These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12002517)

  • 61. The nociceptin orphanin FQ peptide receptor agonist, Ro64-6198, impairs recognition memory formation through interaction with glutamatergic but not cholinergic receptor antagonists.
    Reiss D; Prinssen EP; Wichmann J; Kieffer BL; Ouagazzal AM
    Neurobiol Learn Mem; 2012 Oct; 98(3):254-60. PubMed ID: 22982481
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.
    Bloms-Funke P; Gillen C; Schuettler AJ; Wnendt S
    Peptides; 2000 Jul; 21(7):1141-6. PubMed ID: 10998549
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
    Trapella C; Fischetti C; Pela' M; Lazzari I; Guerrini R; Calo' G; Rizzi A; Camarda V; Lambert DG; McDonald J; Regoli D; Salvadori S
    Bioorg Med Chem; 2009 Jul; 17(14):5080-95. PubMed ID: 19527931
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.
    Peng YL; Chang M; Dong SL; Li W; Han RW; Fu GX; Chen Q; Wang R
    Regul Pept; 2006 May; 134(2-3):75-81. PubMed ID: 16516988
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt
    Cerlesi MC; Ding H; Bird MF; Kiguchi N; Ferrari F; Malfacini D; Rizzi A; Ruzza C; Lambert DG; Ko MC; Calo G; Guerrini R
    Eur J Pharmacol; 2017 Jan; 794():115-126. PubMed ID: 27871910
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats.
    Rutten K; De Vry J; Bruckmann W; Tzschentke TM
    Eur J Pharmacol; 2010 Oct; 645(1-3):119-26. PubMed ID: 20674566
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
    Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
    Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vitro and ex vivo effects of a selective nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N/OFQ and [35S]GTPgammaS in rat brain and spinal cord.
    Yamada S; Kusaka T; Urayama A; Kimura R; Watanabe Y
    Br J Pharmacol; 2003 Aug; 139(8):1462-8. PubMed ID: 12922933
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro characterization of Ac-RYYRWK-NH(2), Ac-RYYRIK-NH(2) and [Phe1Psi(CH(2)-NH)Gly2] nociceptin(1-13)NH(2) at rat native and recombinant ORL(1) receptors.
    Mason SL; Ho M; Nicholson J; McKnight AT
    Neuropeptides; 2001; 35(5-6):244-56. PubMed ID: 12030809
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.
    Rekik K; Faria Da Silva R; Colom M; Pacifico S; Zaveri NT; Calo' G; Rampon C; Frances B; Mouledous L
    Neuropharmacology; 2017 Oct; 125():39-49. PubMed ID: 28705439
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
    Tzschentke TM; Rutten K
    Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
    Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
    Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nociceptin and the NOP receptor in aversive learning in mice.
    Adem A; Madjid N; Kahl U; Holst S; Sadek B; Sandin J; Terenius L; Ögren SO
    Eur Neuropsychopharmacol; 2017 Dec; 27(12):1298-1307. PubMed ID: 29102248
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Detailed In Vitro Pharmacological Characterization of the Clinically Viable Nociceptin/Orphanin FQ Peptide Receptor Antagonist BTRX-246040.
    Ferrari F; Rizzo S; Ruzza C; Calo G
    J Pharmacol Exp Ther; 2020 Apr; 373(1):34-43. PubMed ID: 31937563
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nociceptin/orphanin FQ stimulates human monocyte chemotaxis via NOP receptor activation.
    Trombella S; Vergura R; Falzarano S; Guerrini R; Calo G; Spisani S
    Peptides; 2005 Aug; 26(8):1497-502. PubMed ID: 15922491
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397.
    Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Iwasawa Y; Ohta H
    Eur J Pharmacol; 2000 Jan; 387(3):R17-8. PubMed ID: 10650183
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.
    Seki T; Awamura S; Kimura C; Ide S; Sakano K; Minami M; Nagase H; Satoh M
    Eur J Pharmacol; 1999 Jul; 376(1-2):159-67. PubMed ID: 10440101
    [TBL] [Abstract][Full Text] [Related]  

  • 78. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
    Calo G; Guerrini R; Rizzi A; Salvadori S; Burmeister M; Kapusta DR; Lambert DG; Regoli D
    CNS Drug Rev; 2005; 11(2):97-112. PubMed ID: 16007234
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sodium ions and GTP decrease the potency of [Nphe1]N/OFQ(1-13)NH2 in blocking nociceptin/orphanin FQ receptors coupled to cyclic AMP in N1E-115 neuroblastoma cells and rat olfactory bulb.
    Olianas MC; Onali P
    Life Sci; 2003 May; 72(25):2905-14. PubMed ID: 12697273
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.
    Brookes ZL; Stedman EN; Brown NJ; Hebbes CP; Guerrini R; Calo G; Reilly CS; Lambert DG
    PLoS One; 2013; 8(9):e74943. PubMed ID: 24086402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.